ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2453

Heightened Innate Immune Response to COVID-19 Infection in CKD: Implications to Poorer Outcome During CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Authors

  • Guo, Xiaojia, Yale University School of Medicine, New Haven, Connecticut, United States
  • Xu, Leyuan, Yale University School of Medicine, New Haven, Connecticut, United States
  • Chen, Tian-Min, Yale University School of Medicine, New Haven, Connecticut, United States
  • Gorelick, Fred, Yale University School of Medicine, New Haven, Connecticut, United States
  • Desir, Gary V., Yale University School of Medicine, New Haven, Connecticut, United States
  • Safirstein, Robert L., Yale University School of Medicine, New Haven, Connecticut, United States
Background

Meta-analyses reveal show a significant association of chronic kidney disease (CKD) with severe COVID-19. The double stranded RNA virus SARS-CoV-2 can evoke a damaging inflammatory response. To understand the mechanism for the greater severity of the disease in patients with CKD, we studied an animal model of CKD exposed to polyinosinic-polycytidylic acid [poly(I:C), a synthetic analog of double-stranded RNA that recapitulates the innate immune response provoked by SARS-CoV-2].

Methods

C57Bl6j mice were injected with 2 doses of cisplatin at 15 mg / kg or vehicle control subcutaneously, 2 weeks apart. After CKD established, control and CKD mice were subsequently injected with poly(I:C) at 30 mg/kg intravenously and monitored for body weight loss and mortality. Bone marrow cells were isolated 2 weeks post poly(I:C) treatment and grown in serum-free medium supplemented with macrophage colony stimulation factor for 7 days to obtain bone marrow derived macrophages (BMDM). These cells were stimulated with 10 ug / ml poly (I:C), followed by measurement of proinflammatory cytokines. Single cell RNA sequencing was used to compare transcriptome between normal and CKD kidneys.

Results

CKD animals had elevated plasma creatinine (0.14 ± 0.02 mg / dL, n=8, control mice 0.09 ± 0.01 mg / dL, n=5, p<0.05) and elevated plasma levels kidney injury marker 1 (KIM-1; 133.6 ± 29.9 pg /ml, vs undetectable, n=5, p<0.05). Poly (I:C) treatment induced a greater body weight loss in CKD animals (9.9± 2.9 %, n=8 vs control mice 6.8 ± 2.0 %, n=5, p<0.0005) and greater mortality of CKD mice (46% mortality within 24h in CDK mice vs no mortality in control mice). BMDMs from CKD mice produced greater levels of IL-6 than control BMDM upon poly (I:C) stimulation at both the mRNA and protein levels. In addition, Single cell RNA sequencing revealed that there is 3-fold higher relative number of macrophages in CKD kidneys.

Conclusion

Our results show that CKD mice are more sensitive to foreign double strand RNA insult. BMDM isolated from cisplatin-induced CKD demonstrated a greater innate immune response during CKD. We propose that the inherent hyperinflammatory nature of CKD drives a greater innate immune response in this model of viral injury and may be responsible, at least partially, for the poor outcomes in CKD patients with Covid-19 infection.

Funding

  • NIDDK Support